Neutral Phosphate

Phase 1

UUniversity of Chicago

Neutral Phosphate is one of 4 therapeutic programs targeting Kidney Stones. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Kidney StonesNot yet recruiting

Kidney StonesPhase 1

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Kidney Stones

#DrugCompanyPhaseTrials

Thalitone

Jazz Pharmaceuticals

Approved

1 2

Potassium Iodide

MMeda Pharmaceuticals

Approved

2 3

Alka-Seltzer

AAbbott

Phase 2

1 4

Neutral Phosphate

UUniversity of Chicago

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Kidney Stones

NCT07903961

Clinical

Trials by Indication[1]

Kidney Stones1 trial

Pilot Study of Low-Dose Neutral Phosphate Supplementation for Reducing Urine Calcium and Supersaturation in Patients With Recurrent Calcium Oxalate Kidney Stones and Hypophosphatemia

Not yet recruiting·UUniversity of Chicago·Phase 1·NCT07903961·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Neutral Phosphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Neutral Phosphate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Chicago company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUniversity of Chicago

Neutral Phosphate

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Kidney Stones1 trial

References

Drug Info

Quick Facts

Related News